XTL Biopharmaceuticals Ltd (XTLB) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
No case yet. It builds on the next filing, report or 13F period.
No peer readings for XTL Biopharmaceuticals Ltd yet.
Prev close 2.40 · opened flat. High/low 2.40 at 4:30 am ET, 2.40 at 4:30 am ET.
XTL Biopharmaceuticals Ltd
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Manufacturing
1 managers report a position worth $3,311 between them, and 1 of them hold 80% of it.
tall tick = annual report · 1 on record
XTLB (XTL Biopharmaceuticals Ltd) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.